These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 17038832)

  • 1. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.
    Lee MS; Walker RE; Mendelman PM
    Hum Vaccin; 2005; 1(1):6-11. PubMed ID: 17038832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.
    Haller AA; Mitiku M; MacPhail M
    J Gen Virol; 2003 Aug; 84(Pt 8):2153-2162. PubMed ID: 12867647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
    Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
    J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs.
    Garg R; Latimer L; Gomis S; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2019 Feb; 162():54-60. PubMed ID: 30550799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
    Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
    Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model.
    Van Effelterre T; Hens N; White LJ; Gravenstein S; Bastian AR; Buyukkaramikli N; Cheng CY; Hartnett J; Krishnarajah G; Weber K; Pastor LH
    Clin Infect Dis; 2023 Aug; 77(3):480-489. PubMed ID: 36949605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
    Durbin AP; Karron RA
    Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
    O'Shea TM; Sevick MA; Givner LB
    Pediatr Infect Dis J; 1998 Jul; 17(7):587-93. PubMed ID: 9686723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of vaccines for parainfluenza virus infections.
    Sato M; Wright PF
    Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of respiratory syncytial virus, influenza and parainfluenza viruses to acute respiratory infections in San Luis Potosí, Mexico.
    Noyola DE; Arteaga-Domínguez G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1049-52. PubMed ID: 16371864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan.
    Kaneko M; Watanabe J; Kuwahara M; Ueno E; Hida M; Kinoshita A; Sone T
    J Infect; 2002 May; 44(4):240-3. PubMed ID: 12099731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children.
    Heikkinen T; Ojala E; Waris M
    J Infect Dis; 2017 Jan; 215(1):17-23. PubMed ID: 27738052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.
    Simoes EA; Tan DH; Ohlsson A; Sales V; Wang EE
    Vaccine; 2001 Dec; 20(5-6):954-60. PubMed ID: 11738763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
    Murphy BR; Hall SL; Kulkarni AB; Crowe JE; Collins PL; Connors M; Karron RA; Chanock RM
    Virus Res; 1994 Apr; 32(1):13-36. PubMed ID: 8030364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.